Welcome to our dedicated page for Arcturus Therape SEC filings (Ticker: ARCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcturus Therapeutics Holdings Inc. filings document the regulatory record for a Nasdaq-listed commercial mRNA medicines and vaccines company with common stock registered under the symbol ARCT. Its Form 8-K reports furnish quarterly and annual financial results, corporate updates, Regulation FD presentations, and clinical or product disclosures tied to programs such as LUNAR-CF and KOSTAIVE.
The company’s proxy materials describe annual meeting matters, director elections, executive compensation, governance practices, and stockholder voting procedures. Other filings cover officer and board changes, registered security details, reporting-status notices such as Form 12b-25 notifications, and risk, capital-structure, collaboration, and development-stage disclosure relevant to its RNA therapeutics and vaccine business.
Arcturus Therapeutics Holdings Inc. entered a strategic collaboration with Thermo Fisher Scientific to support the development of ARCT-032, its investigational mRNA therapy for cystic fibrosis. The relationship is governed by a Master Services Agreement and a detailed Project Addendum.
Under the Master Services Agreement, Thermo Fisher will contribute up to $40 million of clinical manufacturing services for ARCT-032, and Arcturus will engage Thermo Fisher’s PPD business for up to $40 million in contract research organization services. If ARCT-032 receives regulatory approval, Thermo Fisher would gain exclusive commercial manufacturing rights for a specified period, to be finalized in a separate supply agreement.
The initial term of the Master Services Agreement is five years, with automatic one-year renewals unless either party gives at least 90 days’ notice. The Project Agreement covers key activities such as technical transfer, engineering and clinical batches, fill-finish, product release, and stability studies, supporting ARCT-032 through late-stage clinical development and potential commercialization.
Arcturus Therapeutics Holdings Inc. director Edward W. Holmes received a grant of stock options as part of his 2026 annual board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share, expiring on June 5, 2036.
According to the footnote, the options vest monthly over one year from the grant date, meaning portions become exercisable each month during that period. This is a compensation-related grant, not an open-market purchase, and leaves Holmes with 15,000 derivative securities reported after the transaction.
Arcturus Therapeutics Holdings Inc. director Peter C. Farrell reported receiving a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $7.3000 per share and expire on June 5, 2036.
The filing describes this as the 2026 annual grant for his service on the Board of Directors. According to the footnote, the shares underlying the option vest monthly over a one-year period from the grant date. After this grant, Farrell holds options for 15,000 shares directly.
Arcturus Therapeutics Holdings Inc. reported that director James F. Barlow received a grant of stock options as part of his 2026 board compensation. The award covers 15,000 options to buy common stock at an exercise price of $7.30 per share.
According to the disclosure, the options vest monthly over a one-year period from the grant date, aligning the director’s compensation with the company’s performance over time. All 15,000 options are shown as held directly following this grant, with an expiration date in 2036.
Arcturus Therapeutics Holdings Inc. director John Markels received a grant of stock options as part of his 2026 annual board compensation. The award covers options to buy 15,000 shares of common stock at an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year from the grant date, and following this grant he holds stock options for 15,000 shares directly.
Arcturus Therapeutics Holdings Inc. director Moncef Slaoui received a grant of stock options as part of annual board compensation. The award covers 15,000 options for Common Stock at an exercise price of $7.30 per share, expiring on June 5, 2036. These options vest monthly over one year from the grant date, and following this grant he holds 15,000 derivative securities directly.
Arcturus Therapeutics Holdings Inc. director Magda Marquet received a grant of stock options covering 15,000 shares of common stock, with an exercise price of $7.30 per share and an expiration date of June 5, 2036. The options vest monthly over one year from the grant date and represent her 2026 annual grant as a member of the company’s Board of Directors.
Arcturus Therapeutics Holdings Inc. reported that director Jing L. Marantz received a grant of stock options covering 15,000 shares of common stock. The options have an exercise price of $7.30 per share and expire on June 5, 2036.
According to the disclosure, these options represent Dr. Marantz’s 2026 annual grant for service on the Board of Directors. The shares underlying the option vest monthly over one year from the grant date, and following this award she holds stock options for 15,000 shares directly.
Arcturus Therapeutics Holdings Inc. reported the results of its 2026 annual meeting of stockholders. A quorum was present, with 21,435,189 shares represented out of 28,423,069 shares entitled to vote. Stockholders elected eight directors, each receiving more than 15.5 million votes in favor and remaining in office until the 2027 annual meeting. They also approved, on a non-binding advisory basis, the company’s named executive officer compensation, with 15,254,240 votes for and 327,647 against. In addition, stockholders ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 21,378,017 votes for and minimal opposition.
Arcturus Therapeutics Holdings Inc. reported that its Chief Financial Officer, Dennis Mulroy, received a grant of employee stock options covering 100,000 shares of common stock. These options have an exercise price of $8.63 per share and expire on May 1, 2036.
The grant was made under the company’s Amended and Restated 2019 Omnibus Equity Incentive Plan as part of equity compensation. The underlying shares vest 25% on May 1, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months, encouraging longer-term alignment with shareholders.